A mean of 17.7 biopsies were obtained from each patient. A prostate cancer diagnosis was assigned to 315 of the 582 patients (54%), of which 255 (81%) were diagnosed based on TRUS-guided biopsy and 253 (80%) by MP-MRI/US-targeted biopsy. Of the 57 cases diagnosed with a clinically significant disease based on TRUS-guided biopsy, an identical diagnosis was assigned in 50 cases based on results of the MP-MRI/US-targeted biopsy, while 5 were diagnosed with a clinically insignificant disease and 2 were diagnosed as normal based on results obtained from the MP-MRI/US- targeted biopsy. Conversely, diagnoses assigned using TRUS-guided biopsies were upgraded based on results of MP-MRI/US targeted biopsies from clinically insignificant to clinically significant in 21 cases, and from normal to clinically significant in 17 cases. Gleason scores were higher in the MP-MRI/US-targeted biopsy than the TRUS-guided biopsy in 81 cases (43 cases were upgraded to clinically insignificant and 38 to clinically significant); however higher Gleason scores were observed among TRUS-guided biopsies in 67 cases (60 cases upgraded to clinically insignificant and 7 to clinically significant). Specimens that displayed discordant Gleason scores among biopsy methods that resulted in a diagnosis upgrade were associated with lower prostate volume (OR=0.84, P=0.0005), higher PSA level (OR=1.03, P=0.004), more lesions (OR=1.4, P=0.004), and higher MRI suspicion level (OR=1.7, P=0.04); but the association with number of lesions was not significant (P=0.6).